# A Study of GR1802 in Participants With Chronic Sinusitis With Nasal Polyps

> **NCT06516302** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Genrix (Shanghai) Biopharmaceutical Co., Ltd.** · enrollment: 228 (estimated)

## Conditions studied

- Chronic Rhinosinusitis With Nasal Polyps

## Interventions

- **DRUG:** GR1802
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06516302
- **Lead sponsor:** Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-09-19
- **Primary completion:** 2026-03
- **Final completion:** 2026-10
- **Target enrollment:** 228 (ESTIMATED)
- **Last updated:** 2026-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06516302

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06516302, "A Study of GR1802 in Participants With Chronic Sinusitis With Nasal Polyps". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06516302. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*